Dana-Farber researchers present major cancer clinical trial results, including AI-driven data analysis, at ESMO Congress 2025.
Key Details
- 1Dana-Farber leads four phase 3 studies in breast, lung, and bladder cancer at ESMO Congress 2025.
- 2Key trials address advanced breast cancer treatment, NSCLC first-line therapy, and ctDNA-guided therapy in bladder cancer.
- 3Patient-reported data from SERENA-6 trial shows improved quality of life for metastatic breast cancer patients.
- 4Presentation of AI-generated synthetic cohorts from a 19,164 patient metastatic breast cancer dataset for real-world data analysis.
- 5Blood biomarker (KIM-1) study may help guide advanced kidney cancer treatment decisions.
- 6ESMO 2025 held in Berlin, Oct 17–21, with global participation.
Why It Matters
The use of AI to generate synthetic cohorts and analyze real-world oncology data can accelerate clinical trials and protect patient privacy, representing significant advancements for radiology, cancer informatics, and AI communities. These developments offer pathways to improved research collaboration and personalized cancer care.
Source
EurekAlert
Related News
•EurekAlert
AI Repurposes Routine CT Scans for Osteoporosis Detection
AI algorithms can extract bone density data from routine CT scans to identify osteoporosis, enabling opportunistic screening.
•EurekAlert
AI Outperforms Radiologists in Detecting Hidden Airway Objects on Chest CT
Southampton researchers developed an AI that surpassed radiologists in detecting hard-to-see airway obstructions on chest CT scans.
•EurekAlert
Zero-Cost EHR-Based AI Tool Scales Dementia Detection in Primary Care
A zero-cost, EHR-integrated AI tool significantly boosts dementia detection in primary care clinics without adding clinician workload.